type 2 diabetes
Conditions
Interventions
Keeping Pioglitazone
Switching Pioglitazone to Dapagliflozin
Sponsors
Hokkaido Unverstiy Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age: 20 to 80 years old 2) HbA1c: 6.0-8.5% 3) BMI: 23 kg/m^2 and more 4) eGFR: 45ml/min/1.73m^2 and more 5) Taking Pioglitazone(15-30 mg per day) for more than 12 weeks 6) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Already taking SGLT2 inhibitor agents 2) With hypersensitivity to Dapagliflozin 3) With severe or unstable retinopathy 4) With severe liver or kidney disfunction 5) With severe diabetic ketosis, pre-coma, or coma 6) With severe infection or trauma, or in perioperation 7) With pregnancy 8) Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body weight and HbA1c at 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Abdominal circumference Blood pressure Lipid metabolism Liver function Complete blood count, renal function, electrolyte Urine test Frequency of hypoglycemia Dose of antidiabetic drugs before and during clinical trial | — |
Countries
Japan
Contacts
Public ContactKyu Yong Cho
Hokkaido Unverstiy Hospital Department of Internal Medicine II
Outcome results
None listed